Reuters reports Cerebras Systems is targeting a valuation of up to $26.62 billion in its U.S. IPO, amid strong investor demand for AI infrastructure and advanced chips. IPOX® Research Associate Lukas Muehlbauer is quoted on Cerebras’ competitive positioning against Nvidia, its role as a signal deal for high-growth AI infrastructure listings, and the potential race to complete offerings before a major SpaceX IPO draws investor attention and capital in the Reuters article published May 4, 2026.

Global IPO activity remains active across major regions, led by large U.S. listing plans from SpaceX, Roze AI, SK Hynix, Tenneco and Pershing Square USA. Europe’s pipeline includes delayed or potential listings from RAC, Dolomiti Energia and BioMar, while Singapore is advancing dual U.S.-Singapore listing rules. In MENA, Saudi Arabia’s DABS IPO is testing investor confidence amid volatility, highlighting selective resilience despite a sharp regional slowdown in issuance across the wider GCC market.

Reuters reported that Bill Ackman’s Pershing Square and Pershing Square USA are set to list on the NYSE after Pershing Square USA raised $5 billion in its IPO. The debut marks Ackman’s renewed effort to bring a flagship U.S.-listed fund to market and tests investor appetite for closed-end funds. IPOX® Research Associate Lukas Muehlbauer was quoted on the offering’s structure, noting that shares of the managing company may have helped support investor demand beyond the fund alone in the listing.

Reuters reported that Rare Earths Americas launched its U.S. IPO roadshow, targeting a valuation of up to $368.4 million amid rising investor interest in critical minerals. The company plans to raise up to $52.8 million and list on NYSE American under “REA”. IPOX® Associate Lukas Muehlbauer was quoted, noting the company’s role in supply-chain diversification and the potential M&A appeal of newly public rare earth companies in a strategically important sector as global demand continues to accelerate sharply worldwide.

Lincoln International has filed for a rare U.S. initial public offering, joining the ranks of publicly traded boutique investment banks like Moelis and Houlihan Lokey. The Chicago-based firm, which reported $214.1 million in net income on $783.8 million in revenue for 2025, is capitalizing on a rebounding global dealmaking environment. IPOX® CEO Josef Schuster highlighted the asset class's resilience against recent geopolitical volatility, stating a "golden age for U.S. IPOs has arrived" amidst strong demand for U.S.-domiciled specialty deals.

A historic tech IPO wave is building, with giants like SpaceX, OpenAI, and Anthropic targeting a combined $3 trillion valuation, signaling a massive shift in public equities. In the U.S., Milan-based Bending Spoons preps a $20 billion listing, while the new Texas Stock Exchange targets a 2027 launch. European markets remain dynamic; Revolut eyes a staggering $200 billion valuation by 2028, and Boots explores a London float. Meanwhile, geopolitical volatility forced telecom operator Digi to postpone its Spanish debut.

Madison Air achieved a blockbuster $15.65 billion NYSE debut, while biotech firm Kailera Therapeutics surged 62%. The pipeline is expanding rapidly, highlighted by AI chipmaker Cerebras targeting a $35 billion valuation alongside major filings from Inspire Brands, Kraken, and EagleRock. As IPOX® experts note, defense tech and software sectors remain robust. Internationally, Syngenta prepares for a massive $10 billion Hong Kong IPO, and Uzbekistan’s sovereign fund secures BlackRock for its upcoming London listing.

Blackstone-backed mobile app marketing firm Liftoff has officially filed for a U.S. IPO on the Nasdaq under the ticker "LFTO." The company previously paused its listing plans amid market volatility but is now capitalizing on a broader rebound in technology stocks and easing geopolitical tensions. IPOX® Research Associate Lukas Muehlbauer provided expert commentary to Reuters, noting that Liftoff is strategically utilizing this reopening IPO window as investors view the recovering software space as increasingly attractive for new equity listings.

IPOX® Research Associate Lukas Muehlbauer was featured in a recent Reuters article discussing Kailera Therapeutics' $625 million IPO. As shares surged 62.5%, the debut signals a potential biotech IPO market turnaround. Muehlbauer highlighted the strong demand for GLP-1 companies, stating, "Obesity remains one of the few areas in biotech with clear investor appetite." He noted near-term trading relies heavily on broader obesity-drug space fundamentals.

Reuters highlighted Madison Air Solutions' highly successful NYSE debut, where shares surged to secure a massive 15.65 billion dollar valuation. Raising 2.23 billion dollars, the HVAC firm achieved the largest industrials listing since 1999, driven by robust demand for AI data center cooling infrastructure. IPOX® Vice President Kat Liu provided expert commentary on the blockbuster offering, noting that its heavy oversubscription and premium pricing signal a definitive return of investor appetite for proven cash generating businesses despite an uneven market.

The number of defense-tech unicorns in North America has risen to 24, four times the 2020 level. Heightened geopolitical risks, including military clashes involving the U.S., Israel, and Iran, are driving investment into defense companies. As unicorns continue to emerge, the initial public offering market is also becoming more active. IPOX® CEO Josef Schuster said, "Because it is less directly affected by stock market volatility, the IPO market in the defense sector is quite robust."

A slew of companies across sectors, from biotech to real estate investment trust, launched IPO roadshows on Monday, as issuers prepare to go ahead with their listing plans amid the Middle East conflict. The IPO market struggled for momentum in February and March as episodes of market volatility sidelined issuers. But "2026 is still on track to be the best year for IPOs since the post-pandemic drought, and it may even get there without the mega listings," said Lukas Muehlbauer.

The U.S. market braces for potential mega-listings from SpaceX and OpenAI, though IPOX® CEO Josef Schuster cautions that even massive debuts face a strict buyer's market. Meanwhile, the defense "supercycle" fuels momentum for aerospace firms like AEVEX and HawkEye 360. In Europe, TK Elevator explores a €25 billion float alongside Terra Quantum's $3.25 billion SPAC deal. In Asia, Seven & i Holdings has delayed its highly anticipated 7-Eleven spin-off to 2027 amid market uncertainty.

IPOX® Associate Muehlbauer highlighted the growing momentum in the space technology sector following HawkEye 360’s U.S. IPO filing. He noted that while the anticipated SpaceX listing acts as a massive thematic catalyst, it could simultaneously divert investor focus from smaller issuers. Muehlbauer observed that HawkEye is strategically entering the public market during a favorable issuance window to manage debt from its recent acquisition of Innovative Signal Analysis, leveraging its 74% revenue jump and transition to profitability to attract disciplined investors.

IPOX® Associate Muehlbauer was featured in a recent Reuters article discussing the drone manufacturer AEVEX’s upcoming $2.35 billion IPO. Providing expert analysis on the growing investor appetite for defense technologies, he highlighted how rising global military spending has created a new defense 'supercycle.' He noted that conflicts in Ukraine and the Middle East underscore the critical role of modern unmanned systems, driving thematic investor interest in the rapidly expanding global drone sector.

IPOX® Associate Muehlbauer was featured in a Bloomberg article discussing the challenges facing European IPOs as lock-up periods expire. With many 2025 listings trading significantly below their offer prices, Muehlbauer noted that while selling at a discount can "lock in a disappointing valuation," strategic follow-on sales may ultimately benefit companies by improving liquidity and reducing market overhang. His analysis highlights the complex balancing act for investors navigating a thawing European equity market and shifting valuation benchmarks.